Harrow (NASDAQ:HROW) Price Target Raised to $64.00 at Craig Hallum

Key Points

• Harrow's price target was increased to $64.00 by Craig Hallum, suggesting a potential upside of 29.61% from its previous close.
• The company reported $0.24 EPS for the quarter, surpassing the consensus estimate of $0.01, but its revenue was slightly below expectations.
• Harrow has received a consensus rating of "Moderate Buy" from analysts, with seven analysts rating it as a "Buy" and one as a "Hold."

Harrow (NASDAQ:HROW - Get Free Report) had its target price hoisted by research analysts at Craig Hallum from $54.00 to $64.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a "buy" rating on the stock. Craig Hallum's price objective suggests a potential upside of 29.61% from the stock's previous close.

Several other research firms also recently commented on HROW. Cantor Fitzgerald initiated coverage on Harrow in a report on Friday, July 11th. They issued an "overweight" rating and a $76.00 price objective for the company. Zacks Research downgraded Harrow from a "strong-buy" rating to a "hold" rating in a report on Friday, September 12th. William Blair began coverage on Harrow in a research note on Tuesday, June 10th. They set an "outperform" rating for the company. HC Wainwright boosted their price target on Harrow from $60.00 to $64.00 and gave the company a "buy" rating in a research note on Wednesday, August 13th. Finally, BTIG Research boosted their price target on Harrow from $62.00 to $63.00 and gave the company a "buy" rating in a research note on Thursday, August 14th. Seven analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, Harrow currently has a consensus rating of "Moderate Buy" and a consensus price target of $64.50.

Harrow Stock Performance

NASDAQ HROW traded up $3.29 during trading hours on Tuesday, hitting $49.38. The company's stock had a trading volume of 182,400 shares, compared to its average volume of 490,351. Harrow has a 12 month low of $20.85 and a 12 month high of $59.23. The company's 50 day simple moving average is $37.49 and its two-hundred day simple moving average is $30.80. The company has a market cap of $1.83 billion, a P/E ratio of -196.25 and a beta of 0.33. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.62 and a quick ratio of 0.58.

Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.01 by $0.23. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%.The company had revenue of $63.74 million during the quarter, compared to the consensus estimate of $64.23 million. Harrow has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Harrow will post -0.53 EPS for the current fiscal year.

Institutional Trading of Harrow

Hedge funds have recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new stake in shares of Harrow during the 4th quarter worth approximately $25,000. Quarry LP purchased a new stake in shares of Harrow during the 1st quarter worth approximately $32,000. Raymond James Financial Inc. purchased a new stake in Harrow during the 2nd quarter valued at $48,000. Tower Research Capital LLC TRC raised its holdings in Harrow by 345.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company's stock valued at $103,000 after buying an additional 2,615 shares during the period. Finally, State of Wyoming purchased a new stake in Harrow during the 1st quarter valued at $97,000. 72.76% of the stock is owned by hedge funds and other institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.